Jordan Armstrong, VP of Business Development at AssistRX, explains how companies can tailor direct-to-patient strategies into their commercialization plans. At this year’s Access USA conference, ...

Cold Chain Technologies (CCT) has announced the upcoming launch of MedAssure, a new cold chain orchestration platform. The platform will be officially introduced at LogiPharma 2026, where the company ...

Brok Vandersteen, VP of Business Development, AssistRX, explains how policy pressures push life sciences companies toward direct-to-patient model adoption. At this year’s Access USA conference, ...

This insight piece explores how treatment patterns in bladder cancer have shifted as immunotherapy options have expanded in community oncology. You’ll learn how combination regimens such as enfortumab ...

In today's Pharma Pulse, ongoing conflict in the Middle East disrupts critical pharmaceutical cold chains, while AstraZeneca and partners launch a new program to decarbonize industrial heat across ...

In the second of his three-part Pharmaceutical Commerce interview, Jay Bregman discusses how rising demand for GLP-1 therapies is challenging employers to reassess how they manage ...

For those managing pharmaceutical supply chains, the transition to low-carbon heat is no longer elective. Evolving regulatory frameworks, such as the European Union’s Carbon Border Adjustment ...

A $3 billion China investment targets localized oral solid-dose manufacturing and supply-chain redundancy to support ...

In today’s Pharma Pulse, the FDA expands a key biologic approval for pediatric patients, and new research highlights the success of pharmacist-led testing in rural communities.

Ongoing conflict in the Middle East has pushed pharmaceutical companies into cold chain rerouting scrambles. Conflict in the Middle East is disrupting pharmaceutical supply chains, as the closure and ...

Orphan drugs are forecast to surpass $400 billion in 2032 sales, driven by accelerating rare disease innovation despite regulatory volatility, pricing pressures, and capital competition from ...